Drug intelligence / Profile preview

GB233

Development stage: Preclinical
Lead developer: Genor Biopharma

Overview

GB233 is an early-stage therapeutic candidate being developed by Genor Biopharma Co., Ltd. for the treatment of cancer. As of current public pipeline disclosures, specific details regarding its molecular target, modality (e.g., monoclonal antibody, small molecule), and precise mechanism of action have not been released. It is part of Genor Biopharma's oncology portfolio, which focuses on innovative biotherapeutics including monoclonal, bispecific, and trispecific antibodies.

Beyond the preview

Go deeper on GB233.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB233.

Explore the full profile